Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.520
+0.040 (2.70%)
At close: Dec 20, 2024, 4:00 PM
1.510
-0.010 (-0.66%)
After-hours: Dec 20, 2024, 6:36 PM EST
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 5.38, with a low estimate of 1.50 and a high estimate of 7.00. The average target predicts an increase of 253.95% from the current stock price of 1.52.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CHRS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +294.74% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +360.53% | Dec 4, 2024 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +163.16% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +689.47% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +689.47% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
261.46M
from 257.24M
Increased by 1.64%
Revenue Next Year
305.85M
from 261.46M
Increased by 16.98%
EPS This Year
-0.58
from -2.53
EPS Next Year
-0.13
from -0.58
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 288.8M | 371.2M | 440.4M | |||
| Avg | 261.5M | 305.9M | 353.1M | |||
| Low | 238.7M | 252.7M | 297.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 12.2% | 42.0% | 44.0% | |||
| Avg | 1.6% | 17.0% | 15.4% | |||
| Low | -7.2% | -3.3% | -2.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.32 | 0.22 | 0.34 | |||
| Avg | -0.58 | -0.13 | -0.22 | |||
| Low | -0.70 | -0.45 | -0.95 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.